Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601

Watchlist Manager
Shenzhen Kangtai Biological Products Co Ltd Logo
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Watchlist
Price: 18.1 CNY -4.99% Market Closed
Market Cap: 20.2B CNY
Have any thoughts about
Shenzhen Kangtai Biological Products Co Ltd?
Write Note

Shenzhen Kangtai Biological Products Co Ltd
Gain/Loss on Disposition of Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Kangtai Biological Products Co Ltd
Gain/Loss on Disposition of Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gain/Loss on Disposition of Assets CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gain/Loss on Disposition of Assets
-ÂĄ1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Kangtai Biological Products Co Ltd
Glance View

Market Cap
20.2B CNY
Industry
Biotechnology

Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. The company is headquartered in Shenzhen, Guangdong and currently employs 2,445 full-time employees. The company went IPO on 2017-02-07. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The firm operates its businesses primary in domestic market.

Intrinsic Value
22.35 CNY
Undervaluation 19%
Intrinsic Value
Price

See Also

Back to Top